The effect of doxapram on fetal rabbit ductus arteriosus

Hiroko Boda; Tadayoshi Hata; Hidetoshi Uchida; Masayuki Fujino; Yoshihiko Eryu; Masatomo Takeuchi; Masafumi Miyata; Hiroko Nomura; Toshio Yamazaki; Tetsushi Yoshikawa

The effect of doxapram on fetal rabbit ductus arteriosus

Hiroko Boda, Tadayoshi Hata, Hidetoshi Uchida, Masayuki Fujino, Yoshihiko Eryu, Masatomo Takeuchi, Masafumi Miyata, Hiroko Nomura, Toshio Yamazaki, Tetsushi Yoshikawa

Research output: Contribution to journal › Article › peer-review

Abstract

Doxapram (DOP) is a respiratory stimulant that has been used as a second-line drug for the treatment of idiopathic apnea of prematurity unresponsive to methylxanthine therapy. The direct action of DOP on blood vessels is poorly understood. Furthermore, no reports have examined the effect of this therapy on the ductus arteriosus, a structure that frequently complicates low birth weight infants. To clarify the effects of the drug on the arterial vessel contractile system, we investigated the direct effect of DOP on the contractile profiles of the ductus arteriosus from fetal rabbit. The concentrations of doxapram used in clinical applications did not demonstrate any depressive or augmentative effects on the contractions of tissue preparations under hypoxic (PO₂ 30 mmHg) conditions. No relaxation of ductal tension was seen following DOP treatment after contraction by hyperoxia (PO ₂ 100-120 mmHg), indomethcin (1 μM), or high-K⁺ (120 mM). Our results indicate that therapeutic concentrations of DOP do not demonstrate any direct effects on the contractile mechanism of the ductus arteriosus in fetal rabbits.

Original language	English
Pages (from-to)	547-554
Number of pages	8
Journal	Therapeutic Research
Volume	32
Issue number	4
Publication status	Published - 20-04-2011

All Science Journal Classification (ASJC) codes

General Medicine

Cite this

@article{a298305681474b1781c83bf012576f99,

title = "The effect of doxapram on fetal rabbit ductus arteriosus",

abstract = "Doxapram (DOP) is a respiratory stimulant that has been used as a second-line drug for the treatment of idiopathic apnea of prematurity unresponsive to methylxanthine therapy. The direct action of DOP on blood vessels is poorly understood. Furthermore, no reports have examined the effect of this therapy on the ductus arteriosus, a structure that frequently complicates low birth weight infants. To clarify the effects of the drug on the arterial vessel contractile system, we investigated the direct effect of DOP on the contractile profiles of the ductus arteriosus from fetal rabbit. The concentrations of doxapram used in clinical applications did not demonstrate any depressive or augmentative effects on the contractions of tissue preparations under hypoxic (PO2 30 mmHg) conditions. No relaxation of ductal tension was seen following DOP treatment after contraction by hyperoxia (PO 2 100-120 mmHg), indomethcin (1 μM), or high-K+ (120 mM). Our results indicate that therapeutic concentrations of DOP do not demonstrate any direct effects on the contractile mechanism of the ductus arteriosus in fetal rabbits.",

author = "Hiroko Boda and Tadayoshi Hata and Hidetoshi Uchida and Masayuki Fujino and Yoshihiko Eryu and Masatomo Takeuchi and Masafumi Miyata and Hiroko Nomura and Toshio Yamazaki and Tetsushi Yoshikawa",

year = "2011",

month = apr,

day = "20",

language = "English",

volume = "32",

pages = "547--554",

journal = "Therapeutic Research",

issn = "0289-8020",

publisher = "Life Science Publishing Co. Ltd",

number = "4",

}

TY - JOUR

T1 - The effect of doxapram on fetal rabbit ductus arteriosus

AU - Boda, Hiroko

AU - Hata, Tadayoshi

AU - Uchida, Hidetoshi

AU - Fujino, Masayuki

AU - Eryu, Yoshihiko

AU - Takeuchi, Masatomo

AU - Miyata, Masafumi

AU - Nomura, Hiroko

AU - Yamazaki, Toshio

AU - Yoshikawa, Tetsushi

PY - 2011/4/20

Y1 - 2011/4/20

N2 - Doxapram (DOP) is a respiratory stimulant that has been used as a second-line drug for the treatment of idiopathic apnea of prematurity unresponsive to methylxanthine therapy. The direct action of DOP on blood vessels is poorly understood. Furthermore, no reports have examined the effect of this therapy on the ductus arteriosus, a structure that frequently complicates low birth weight infants. To clarify the effects of the drug on the arterial vessel contractile system, we investigated the direct effect of DOP on the contractile profiles of the ductus arteriosus from fetal rabbit. The concentrations of doxapram used in clinical applications did not demonstrate any depressive or augmentative effects on the contractions of tissue preparations under hypoxic (PO2 30 mmHg) conditions. No relaxation of ductal tension was seen following DOP treatment after contraction by hyperoxia (PO 2 100-120 mmHg), indomethcin (1 μM), or high-K+ (120 mM). Our results indicate that therapeutic concentrations of DOP do not demonstrate any direct effects on the contractile mechanism of the ductus arteriosus in fetal rabbits.

AB - Doxapram (DOP) is a respiratory stimulant that has been used as a second-line drug for the treatment of idiopathic apnea of prematurity unresponsive to methylxanthine therapy. The direct action of DOP on blood vessels is poorly understood. Furthermore, no reports have examined the effect of this therapy on the ductus arteriosus, a structure that frequently complicates low birth weight infants. To clarify the effects of the drug on the arterial vessel contractile system, we investigated the direct effect of DOP on the contractile profiles of the ductus arteriosus from fetal rabbit. The concentrations of doxapram used in clinical applications did not demonstrate any depressive or augmentative effects on the contractions of tissue preparations under hypoxic (PO2 30 mmHg) conditions. No relaxation of ductal tension was seen following DOP treatment after contraction by hyperoxia (PO 2 100-120 mmHg), indomethcin (1 μM), or high-K+ (120 mM). Our results indicate that therapeutic concentrations of DOP do not demonstrate any direct effects on the contractile mechanism of the ductus arteriosus in fetal rabbits.

UR - http://www.scopus.com/inward/record.url?scp=79956365881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956365881&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79956365881

SN - 0289-8020

VL - 32

SP - 547

EP - 554

JO - Therapeutic Research

JF - Therapeutic Research

IS - 4

ER -

The effect of doxapram on fetal rabbit ductus arteriosus

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this